Is Hypoglycemia Secondary to Metastatic Retroperitoneal Sarcoma - A Therapeutic Challenge? Case Report and Review of Literature

Curr Probl Cancer. 2023 Jun;47(3):100961. doi: 10.1016/j.currproblcancer.2023.100961. Epub 2023 May 14.

Abstract

Most soft tissue sarcomas afflict the extremities; however, the retro peritoneum can also be affected rarely. Retroperitoneal sarcomas are relatively asymptomatic. Although tumor-induced hypoglycemia is rare in tumors other than insulinomas, extrapancreatic tumors are a subset that displays this phenomenon. The occurrence of hypo-insulinemic hypoglycemia with low GH and IGF-1 should prompt consideration of the secretion of a hypoglycemic substance impeding the secretion of insulin and GH, such as IGF-2 or one of its related substances. The present case report is of a 38-year-old male with retroperitoneal round cell sarcoma with liver metastasis with severe symptomatic hypoglycemia who was managed with multipronged symptomatic therapy and oncological management after which he had shown significant improvement in hypoglycemic episodes and symptom profile. A literature review revealed our case report to be the first reported case of a young male (preponderance in the older population) with hypoglycemia associated with retroperitoneal sarcoma which presented with liver metastasis and the only one treated with Gemcitabine /Docetaxel. The presence of these features might point toward a poorer prognosis in a disease with an already dismal course. All these points towards the need for further research regarding intensified oncological treatment after evidence-based prognostication of high-risk groups and modalities for the management of symptomatic hypoglycemia such as Somatostatin analogs and glucagon which aid in symptom control.

Keywords: Hypoglycemia; IGF-2; Metastatic sarcoma; NICTH; Retroperitoneal sarcoma.

Publication types

  • Review
  • Case Reports

MeSH terms

  • Adult
  • Humans
  • Hypoglycemia* / diagnosis
  • Hypoglycemia* / drug therapy
  • Hypoglycemia* / etiology
  • Hypoglycemic Agents / therapeutic use
  • Liver Neoplasms* / secondary
  • Male
  • Retroperitoneal Neoplasms* / complications
  • Retroperitoneal Neoplasms* / drug therapy
  • Sarcoma* / complications
  • Sarcoma* / therapy

Substances

  • Hypoglycemic Agents